Autologous multi-antigen-specific cytotoxic T lymphocytes

自体多抗原特异性细胞毒性T淋巴细胞

Report date: 2022/11/05 16:26:06

Base Information

Drug NameAutologous multi-antigen-specific cytotoxic T lymphocytes
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesImmuclin Biomed Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesImmuclin Biomed Inc
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A